Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis


Por: Aymerich C, Pedruzo B, Salazar de Pablo G, Labad J, McCutcheon R, Pillinger T, González-Torres MÁ, Sanchez-Gistau V, Oliver D, Alonso-Alconada D, Navalón P, Sugranyes G, Vieta E, Arango C, McGuire P, Fusar-Poli P and Catalan A

Publicada: 1 ago 2025 Ahead of Print: 1 abr 2025
Resumen:
First episode psychosis (FEP) individuals show biological abnormalities preceding antipsychotic treatment. However, it remains unclear whether such alterations are also present before the onset of psychosis. We aim to provide estimates of standardized mean differences for immune, cardiometabolic, prolactin, and HPA axis parameters in individuals at clinical high-risk for psychosis (CHR-P) compared to healthy controls (HC) and FEP individuals, and between CHR-P transitioning to psychosis (CHR-T) compared non-transitioning (CHR-NT). A multistep literature search was performed from database inception until September 25, 2023. PRISMA/MOOSEcompliant and pre-registered (PROSPERO: CRD42024507670) systematic review identified studies reporting on immune, cardiovascular or endocrine parameters in CHR-P samples compared with HC or FEP samples or comparing CHR-T vs CHR-NT. Inter-group differences in magnitude of effect were estimated using Hedges g and estimates were pooled using random-effects meta-analysis. Heterogeneity was high for most outcomes. 37 studies were included, total sample 2509 CHR-P, 710 FEP, and 1444 HC individuals. A statistically significant elevation of pro-inflammatory proteins was found among CHR-P compared with HC (k = 12; N = 1710; g = 0.16; p < 0.01) and FEP (k = 7; g = 0.15; p = 0.04) subjects. Interleukin-6 (IL-6) was increased in CHR-P compared to HC (k = 9; N = 1243; g = 0.54; p < 0.01), and interleukin-4 (IL-4) was increased in CHR-T compared with CHR-NT (k = 2; N = 318; g = 0.36; p < 0.01). CHR-P exhibited stronger cortisol awakening response than FEP subjects (k = 3; N = 173; g = 0.51; p = 0.01). CHR-P and FEP individuals did not show statistically significant differences in terms of prolactin levels. An inflammatory state (particularly marked by elevated IL-6 and IL-4 levels) and HPA axis alterations are present in CHR-P individuals.

Filiaciones:
Aymerich C:
 Psychiatry Department, Basurto University Hospital, Biobizkaia Health Research Institute, OSI Bilbao-Basurto, University of the Basque Country, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Bilbao, Spain

 Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

Pedruzo B:
 Psychiatry Department, Basurto University Hospital, Biobizkaia Health Research Institute, OSI Bilbao-Basurto, University of the Basque Country, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Bilbao, Spain

Salazar de Pablo G:
 Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

 Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain

 Child and Adolescent Mental Health Services, South London and Maudsley NHS Foundation Trust, London, UK

:
 Department of Mental Health, Consorci Sanitari del Maresme, Mataró, Institut de Neurociències, Translational Neuroscience Research Unit I3PT-INc-UAB, Institut d'Investigació I Innovació Parc Taulí (I3PT), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain

McCutcheon R:
 Department of Psychiatry, University of Oxford, Oxford Health NHS Foundation Trust, Oxford, UK

 Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK

 Oxford Health NHS Foundation Trust, Oxford, UK

Pillinger T:
 Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London. London, UK

González-Torres MÁ:
 Psychiatry Department, Basurto University Hospital, Biobizkaia Health Research Institute, OSI Bilbao-Basurto, University of the Basque Country, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Bilbao, Spain

Sanchez-Gistau V:
 Hospital Universitari Institut Pere Mata of Reus, Reus, Spain

 Institut d'Investigació Sanitària Pere Virgili (IISPV-CERCA), Tarragona, Spain

 Universitat Rovira i Virgili (URV), Reus, Spain

 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Reus, Spain

Oliver D:
 Department of Psychiatry, University of Oxford, NIHR Oxford Health Biomedical Research Centre. Oxford, UK

Alonso-Alconada D:
 Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain

Navalón P:
 Department of Psychiatry and Clinical Psychology, La Fe University and Polytechnical Hospital, Valencia, Spain

 Mental Health Research Unit, Health Research Institute La Fe, Valencia, Spain

Sugranyes G:
 Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Hospital Clínic de Barcelona. Fundació de Recerca Clínic Barcelona, Institut d'Investigacions Biomèdiques Agustí Pi I Sunyer (IDIBAPS). Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain

Vieta E:
 Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Hospital Clínic de Barcelona. Fundació de Recerca Clínic Barcelona, Institut d'Investigacions Biomèdiques Agustí Pi I Sunyer (IDIBAPS). Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain

Arango C:
 Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón School of Medicine, Universidad Complutense, IiSGM, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain

McGuire P:
 Department of Psychiatry, University of Oxford, Oxford Health NHS Foundation Trust. NIHR Oxford Health Biomedical Research Centre, Oxford, UK

Fusar-Poli P:
 Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, London, UK

 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

 Outreach and Support in South-London (OASIS) Service, South London and Maudsley (SLaM) NHS Foundation Trust, London, UK

 Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilian-University (LMU), Munich, Germany

Catalan A:
 Psychiatry Department, Basurto University Hospital, Biobizkaia Health Research Institute, OSI Bilbao-Basurto, University of the Basque Country, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Bilbao, Spain

 Department of Psychiatry, University of Oxford, Oxford Health NHS Foundation Trust, Oxford, UK
ISSN: 08891591





BRAIN BEHAVIOR AND IMMUNITY
Editorial
Elsevier Inc., 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 128 Número:
Páginas: 219-233
WOS Id: 001473240100001
ID de PubMed: 40204113
imagen Green Published, hybrid

MÉTRICAS